Roivant Sciences Ltd [NASDAQ: ROIV] stock went on an upward path that rose over 2.76% on Tuesday, amounting to a one-week price increase of more than 2.31%. The company report on November 13, 2023 at 7:00 AM that Roivant Reports Financial Results for the Second Quarter Ended September 30, 2023, and Provides Business Update.
Roivant entered into a definitive agreement with Roche for the sale of Telavant for $7.1B upfront and a milestone payment of $150M payable upon the initiation of a Phase 3 trial in ulcerative colitis.
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
IMVT-1402 subcutaneous (SC) doses achieved peak Immunoglobulin G (IgG) reductions that are similar to those previously observed with batoclimab, based on initial results from Phase 1 single-ascending dose and 300 mg multiple-ascending dose studies.
Over the last 12 months, ROIV stock rose by 80.23%. The one-year Roivant Sciences Ltd stock forecast points to a potential upside of 41.06. The average equity rating for ROIV stock is currently 1.20, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $7.36 billion, with 760.14 million shares outstanding and 534.13 million shares in the current float. Compared to the average trading volume of 6.33M shares, ROIV stock reached a trading volume of 4974326 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Roivant Sciences Ltd [ROIV]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ROIV shares is $15.78 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ROIV stock is a recommendation set at 1.20. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Guggenheim have made an estimate for Roivant Sciences Ltd shares, keeping their opinion on the stock as Buy, with their previous recommendation back on October 17, 2023.
The Average True Range (ATR) for Roivant Sciences Ltd is set at 0.51, with the Price to Sales ratio for ROIV stock in the period of the last 12 months amounting to 71.35. The Price to Book ratio for the last quarter was 7.85, with the Price to Cash per share for the same quarter was set at 1.79.
ROIV Stock Performance Analysis:
Roivant Sciences Ltd [ROIV] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 2.31. With this latest performance, ROIV shares dropped by -8.73% in over the last four-week period, additionally plugging by 6.41% over the last 6 months – not to mention a rise of 80.23% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ROIV stock in for the last two-week period is set at 49.22, with the RSI for the last a single of trading hit 54.93, and the three-weeks RSI is set at 46.95 for Roivant Sciences Ltd [ROIV]. The present Moving Average for the last 50 days of trading for this stock 10.17, while it was recorded at 8.94 for the last single week of trading, and 9.56 for the last 200 days.
Insight into Roivant Sciences Ltd Fundamentals:
Reflecting on the efficiency of the workforce at the company, Roivant Sciences Ltd [ROIV] managed to generate an average of -$193,201 per employee.Roivant Sciences Ltd’s liquidity data is similarly interesting compelling, with a Quick Ratio of 5.82 and a Current Ratio set at 5.84.
Roivant Sciences Ltd [ROIV] Institutonal Ownership Details
The top three institutional holders of ROIV stocks are: VANGUARD GROUP INC with ownership of 1.3 billion shares, which is approximately 8.2579%. BLACKROCK INC., holding 1.04 billion shares of the stock with an approximate value of $201.66 billion in ROIV stocks shares; and BERKSHIRE HATHAWAY INC, currently with $177.59 billion in ROIV stock with ownership which is approximately 5.7994%.
